Health professionals and the Center for Genetic Engineering and Biotechnology (CIGB) are assessing from today the efficacy of the Cuban anti-COVID-19 Abdala vaccine candidate, after concluding the application of the immunogen in the volunteers of the phase III clinical trial.

Cuba studied 22,938 samples for COVID 19, resulting in 932 positive ones. The country accumulates 3, 700,029 samples taken and 109,625 positive.

The National Coordinating Center for Clinical Trials (CENCEC) strives to keep complying with the Good Clinical Practices and to maintain its certification of its Quality Management System, in accordance with the requirements of the ISO 9001 Standard, a status it has held since 2008, granted by the National Bureau of Standards and AENOR International.

A project to determine the genetic predisposition of patients with Spinocerebellar Ataxia type II (SCA2) to become infected with COVID-19 is under way by specialists in this province, top of the list in prevalence of this disease in Cuba.

Cuba studied 22,451 samples for COVID 19, resulting in 1,046 positive ones. The country accumulates 3, 631,470 samples taken and 106,707 positive.

 Dr. Francisco Duran, national director of epidemiology of the Cuban ministry of public health ( MINSAP by its Spanish acronym) reported today in Havana that at the close of the last day there were 1,046 new cases of COVID-19 in Cuba and 12 deaths due to complications associated with the infection.

As part of the measures to tackle COVID-19 in the province of Holguin, the health system is expanding community population studies as part of the strategies to prevent infection with such a highly contagious virus.

A study by the National School of Public Health (ENSAP), together with the National Group of Health Psychology and other institutions, showed that our health workers are highly committed to, and happy to help in, the fight against COVID-19, a fact that favors work-related stress-response dampening.

The administration of the final dose of Abdala in the eastern region and the third one of Soberana 02 in Havana, together with the development of intervention studies, mark the progress of clinical trials of the Cuban vaccine candidates toward their certification and the subsequent vaccination of the entire Cuban population.

Doctor Antonio Vallin Garcia, General Director of Aica Laboratories, said that between 280 and 300 thousand doses of the Abdala candidate are produced every other day and there are currently three batches on an industrial scale.

Some 26 thousand inhabitants of the Cuban central province of Sancti Spíritus will be immunized against COVID-19 in the coming month of May, with the application of the Abdala vaccine candidate, developed by the Center for Genetic Engineering and Biotechnology of Havana.

 Havana authorities decided to increase the number of healthcare facilities to assist new COVID-19 cases and suspects of having the virus, in the face of a worsening spread of the coronavirus over the past weeks.

Experts from the Cuban ministry of public health (MINSAP by its Spanish acronym) warn about the high number of children, adolescents and young people who continue to be diagnosed with COVID-19, even in the midst of the restrictions and measures adopted in the country.

Thirty-five years after its creation, the Doctor Carlos Miyares Cao Placental Histotherapy Center (Hisplacen) is consolidated as an international reference institution in the research, development, production and commercialization of medicines, cosmetics and nutrients derived from human placenta.